Literature DB >> 33987801

MicroRNAs as therapeutic targets in breast cancer metastasis.

Fahima Danesh Pouya1, Yousef Rasmi2,3, Maria Gazouli4, Eleni Zografos4, Mohadeseh Nemati1.   

Abstract

Breast cancer is a complex disease with multiple risk factors involved in its pathogenesis. Among these factors, microRNAs are considered for playing a fundamental role in the development and progression of malignant breast tumors. In recent years, various studies have demonstrated that several microRNAs exhibit increased or decreased expression in metastatic breast cancer, acting as indicators of metastatic potential in body fluids and tissue samples. The identification of these microRNA expression patterns could prove instrumental for the development of novel therapeutic molecules that either mimic or inhibit microRNA action. Additionally, an efficient delivery system mediated by viral vectors, nonviral carriers, or scaffold biomaterials is a prerequisite for implementing microRNA-based therapies; therefore, this review attempts to highlight essential microRNA molecules involved in the metastatic process of breast cancer and discuss recent advances in microRNA-based therapeutic approaches with potential future applications to the treatment sequence of breast cancer.
© 2021. Controlled Release Society.

Entities:  

Keywords:  Breast cancer; Metastasis; MicroRNA; Vector

Mesh:

Substances:

Year:  2021        PMID: 33987801     DOI: 10.1007/s13346-021-00999-2

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  162 in total

Review 1.  Development and validation of gene expression profile signatures in early-stage breast cancer.

Authors:  Christine Desmedt; Christos Sotiriou; Martine J Piccart-Gebhart
Journal:  Cancer Invest       Date:  2009-01       Impact factor: 2.176

Review 2.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 3.  Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA.

Authors:  Michael J Duffy; Enda W McDermott; John Crown
Journal:  Tumour Biol       Date:  2018-05

4.  Breast cancer statistics, 2015: Convergence of incidence rates between black and white women.

Authors:  Carol E DeSantis; Stacey A Fedewa; Ann Goding Sauer; Joan L Kramer; Robert A Smith; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-10-29       Impact factor: 508.702

5.  Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015).

Authors:  Fatima Cardoso; Danielle Spence; Shirley Mertz; Dian Corneliussen-James; Kimberly Sabelko; Julie Gralow; Maria-João Cardoso; Fedro Peccatori; Diego Paonessa; Ann Benares; Naomi Sakurai; Marc Beishon; Sarah-Jane Barker; Musa Mayer
Journal:  Breast       Date:  2018-04-19       Impact factor: 4.380

6.  Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.

Authors:  Fiona M Blows; Kristy E Driver; Marjanka K Schmidt; Annegien Broeks; Flora E van Leeuwen; Jelle Wesseling; Maggie C Cheang; Karen Gelmon; Torsten O Nielsen; Carl Blomqvist; Päivi Heikkilä; Tuomas Heikkinen; Heli Nevanlinna; Lars A Akslen; Louis R Bégin; William D Foulkes; Fergus J Couch; Xianshu Wang; Vicky Cafourek; Janet E Olson; Laura Baglietto; Graham G Giles; Gianluca Severi; Catriona A McLean; Melissa C Southey; Emad Rakha; Andrew R Green; Ian O Ellis; Mark E Sherman; Jolanta Lissowska; William F Anderson; Angela Cox; Simon S Cross; Malcolm W R Reed; Elena Provenzano; Sarah-Jane Dawson; Alison M Dunning; Manjeet Humphreys; Douglas F Easton; Montserrat García-Closas; Carlos Caldas; Paul D Pharoah; David Huntsman
Journal:  PLoS Med       Date:  2010-05-25       Impact factor: 11.069

Review 7.  The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade.

Authors:  Britta Weigelt; Frederick L Baehner; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

Review 8.  Targeting metastasis.

Authors:  Patricia S Steeg
Journal:  Nat Rev Cancer       Date:  2016-04       Impact factor: 60.716

Review 9.  Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.

Authors:  Xiaofeng Dai; Liangjian Xiang; Ting Li; Zhonghu Bai
Journal:  J Cancer       Date:  2016-06-23       Impact factor: 4.207

10.  Defining the optimal sequence for the systemic treatment of metastatic breast cancer.

Authors:  J A Mestres; A B iMolins; L C Martínez; J I C López-Muñiz; E C Gil; A de Juan Ferré; S Del Barco Berrón; Y F Pérez; J G Mata; A G Palomo; J G Gregori; P G Pardo; J J I Mañas; A L Hernández; E M de Dueñas; N M Jáñez; S M Murillo; J S Bofill; P Z Auñón; P Sanchez-Rovira
Journal:  Clin Transl Oncol       Date:  2016-06-17       Impact factor: 3.405

View more
  2 in total

Review 1.  MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil.

Authors:  Fahima Danesh Pouya; Maria Gazouli; Yousef Rasmi; Dimitra Ioanna Lampropoulou; Mohadeseh Nemati
Journal:  Mol Biol Rep       Date:  2022-02-25       Impact factor: 2.742

2.  Butein-instigated miR-186-5p-dependent modulation of TWIST1 affects resistance to cisplatin and bioenergetics of Malignant Pleural Mesothelioma cells.

Authors:  Mario Cioce; Daniela Rutigliano; Annamaria Puglielli; Vito Michele Fazio
Journal:  Cancer Drug Resist       Date:  2022-07-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.